Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

This phase I trial is to find out the possible side effects of pembrolizumab and radiation therapy before and during surgery in treating patients with head and neck squamous cell cancer that remains despite treatment (persistent) or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays or protons to kill tumor cells and shrink tumors. Giving pembrolizumab and radiation therapy before and during

Trial Details

NCT ID
NCT04754321
Phase
PHASE1
Sponsor
Ohio State University Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • External Beam Radiation Therapy
  • Intraoperative Radiation Therapy
  • Pembrolizumab
  • Quality-of-Life Assessment
  • Salvage Surgery
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Pathologically confirmed either persistent and/ or locoregionally recurrent HNSCC of oral cavity, pharynx, larynx, unknown primary head and neck (H…
  • Resectable disease as determined by the surgeon and team
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) \< 2
  • At least 18 years of age

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →